caa a22 4500 445293063 CHVBK 20180317142534.0 cr unu---uuuuu 170323e20100201xx s 000 0 eng 10.1007/s11626-009-9257-7 doi (NATIONALLICENCE)springer-10.1007/s11626-009-9257-7 Bruno John Operational Technologies Corporation, 4100 NW Loop 410, Suite 230, 78229, San Antonio, TX, USA aut Aptamer-biotin-streptavidin-C1q complexes can trigger the classical complement pathway to kill cancer cells [Elektronische Daten] [John Bruno] Nucleic acid aptamers are regarded as rivals for antibodies and as such are being investigated for their therapeutic potential. In the present work, it is shown that two different high-affinity DNA aptamers developed previously by Ferreira et al. against MUC1 antigen (designated MUC1-5TR-1 and MUC1-S1.3/S2.2) on MCF7 breast cancer cells can be linked to the first component of complement (C1q) via a biotin-streptavidin system and induce significant killing of MCF7 cells in vitro. Cell viability was assessed by Trypan blue uptake and absorbance at 590nm of stained cells following buffer washes and lysis in 1% SDS. While the killing effect is demonstrable versus various controls, dependent on aptamer dose, and reproducible, it appears to kill maximally about half of treated MCF7 cells. Possible reasons for the marginal killing effect include antigenic shedding in vitro and membrane-bound complement regulatory proteins (mCRPs) on the cell surface such as CD46, CD55, and CD59 which act to inhibit complement-mediated lysis of cells. Future in vitro research could benefit from application of mCRP-specific aptamers in combination with anti-MUC1 aptamers to overcome surface protective mechanisms while attacking the plasma membrane of MCF7 cells or other MUC1-expressing cancer cells. However, in vivo such a combination could have deleterious effects on normal MUC1-expressing cells as well. The Society for In Vitro Biology, 2009 Aptamer nationallicence Cancer nationallicence Complement nationallicence DNA nationallicence MCF7 nationallicence Quantum dot nationallicence SELEX nationallicence In Vitro Cellular & Developmental Biology - Animal Springer-Verlag 46/2(2010-02-01), 107-113 1071-2690 46:2<107 2010 46 11626 https://doi.org/10.1007/s11626-009-9257-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11626-009-9257-7 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Bruno John Operational Technologies Corporation, 4100 NW Loop 410, Suite 230, 78229, San Antonio, TX, USA aut NATIONALLICENCE 773 0- In Vitro Cellular & Developmental Biology - Animal Springer-Verlag 46/2(2010-02-01), 107-113 1071-2690 46:2<107 2010 46 11626 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer